Details

Autor(en) / Beteiligte

• Bednar, Erica M
• Paiz, Keiry A
• Lu, Karen H
• Soares Dias De Souza, Aline Patricia
• Oliveira, Gabriela
• Andrade, Carlos e Eduardo Mattos da Cunha
• Gallardo, Lenny
• Rubio-Cordero, Jairo
• Cantu-de-León, David
• Rauh-Hain, Jose Alejandro
• Stockman, Liz

Titel

Delivery of hereditary cancer genetics services to patients newly diagnosed with ovarian and endometrial cancers at three gynecologic oncology clinics in the USA, Brazil, and Mexico

Ist Teil von

• International journal of gynecological cancer, 2024-07, Vol.34 (7), p.1020-1026

Ort / Verlag

England: BMJ Publishing Group Ltd

Erscheinungsjahr

2024

Beschreibungen/Notizen

• ObjectiveThree gynecologic oncology clinics located in the USA, Brazil, and Mexico collaborated to evaluate their delivery of hereditary cancer genetics services. This descriptive retrospective review study aimed to establish baseline rates and timeliness of guideline-recommended genetics service delivery to patients with ovarian, fallopian tube, primary peritoneal (ovarian), and endometrial cancers at each clinic.MethodsPatients who were newly diagnosed with ovarian and endometrial cancers between September 1, 2018 and December 31, 2020 were identified from the medical records of the clinics. Genetics service delivery metrics included the rates of mismatch repair deficiency tumor testing for patients with endometrial cancer (microsatellite instability/immunohistochemistry, MSI/IHC), referral to genetics services for patients with ovarian cancer, completed genetics consultations, and germline genetic testing for patients with ovarian and endometrial cancers. Timeliness was calculated as the average number of days between diagnosis and the relevant delivery metric. Descriptive statistics were used to analyze data.ResultsIn total, 1195 patients (596 with ovarian cancer, 599 with endometrial cancer) were included in the analysis, and rates of genetics service delivery varied by clinic. For patients with ovarian cancer, referral rates ranged by clinic from 32.6% to 89.5%; 30.4–65.1% of patients completed genetics consultation and 32.6–68.7% completed genetic testing. The timeliness to genetic testing for patients with ovarian cancer ranged by clinic from 107 to 595 days. A smaller proportion of patients with endometrial cancer completed MSI/IHC testing (10.0–69.2%), with the average time to MSI/IHC ranging from 15 to 282 days. Rates of genetics consultation among patients with endometrial cancer ranged by clinic from 10.8% to 26.0% and 12.5–16.6% completed genetic testing.ConclusionsAll clinics successfully established baseline rates and timeliness of delivering hereditary cancer genetics services to patients with ovarian and endometrial cancers. Lower rates of delivering genetics services to patients with endometrial cancer warrant additional research and quality improvement efforts.